Department of Medical Oncology, Institute of Oncology Ljubljana, Ljubljana, Slovenia.
Faculty of Medicine, University of Ljubljana, Ljubljana, Slovenia.
Radiol Oncol. 2024 Sep 15;58(3):416-424. doi: 10.2478/raon-2024-0048. eCollection 2024 Sep 1.
To review the characteristics of all Slovenian patients with ocular adnexal lymphoma (OAL) in the period of 24 years with the aim of evaluating demographic data, lymphoma location and type, disease stage, treatment modality, local control rate and survival rate.
All patients with histologically diagnosed OAL in the main tertiary centre of Slovenia, Eye Hospital, University Medical Centre Ljubljana, who were treated at Institute of Oncology Ljubljana were included in the study. Patients' data were collected from October 1995 through April 2019.
Seventy-four patients were included in the study having a median age of 68 years at diagnosis. The majority of lymphomas were of B-cell origin (98.6%). The most frequent type was the extranodal marginal zone B-cell lymphoma (MALT) (71.6%). Orbital lymphomas were diagnosed in 56 cases (75.7%) and conjunctival in 18 cases (24.3%). Ocular manifestation was the first sign of the disease in 78.4% of patients and in 67.6% of patients ocular adnexa were the only disease location. Fifty-one patients (68.9%) were treated with radiotherapy, 7 patients (9.4%) with systemic treatment, 5 patients (6.8%) with combined radiotherapy and systemic treatment and in 11 patients, biopsy and active surveillance strategy was applied (14.9%). Local control of the disease was achieved in 96.6% of treated patients. Median overall survival of the whole study group has not been reached yet. Five-year overall survival rate was 80.1% (95% CI 68.1% - 88.5%) and 5-year lymphoma specific survival rate was 87.2% (95% CI 83.2%-91.2%).
OALs comprise a group of heterogeneous diseases with variable outcomes depending predominately on the patient's age and lymphoma type, with low grade lymphomas carrying good prognosis even in elderly patients.
回顾 24 年来所有斯洛文尼亚眼部附属器淋巴瘤（OAL）患者的特征，旨在评估人口统计学数据、淋巴瘤位置和类型、疾病分期、治疗方式、局部控制率和生存率。
本研究纳入了在斯洛文尼亚主要三级中心、卢布尔雅那大学医学中心眼科医院经组织学诊断为 OAL 的所有患者，并在卢布尔雅那肿瘤研究所接受治疗。从 1995 年 10 月至 2019 年 4 月收集患者数据。
本研究共纳入 74 例患者，诊断时的中位年龄为 68 岁。大多数淋巴瘤来源于 B 细胞（98.6%）。最常见的类型是结外黏膜相关边缘区 B 细胞淋巴瘤（MALT）（71.6%）。56 例（75.7%）为眼眶淋巴瘤，18 例（24.3%）为结膜淋巴瘤。78.4%的患者以眼部表现为首发症状，67.6%的患者仅眼部附属器有病变。51 例（68.9%）患者接受放疗，7 例（9.4%）患者接受全身治疗，5 例（6.8%）患者接受放疗联合全身治疗，11 例（14.9%）患者行活检和主动监测策略。接受治疗的患者中，96.6%的疾病得到局部控制。全组患者中位总生存时间尚未达到。5 年总生存率为 80.1%（95%CI 68.1% - 88.5%），5 年淋巴瘤特异性生存率为 87.2%（95%CI 83.2%-91.2%）。
OAL 是一组异质性疾病，其结果主要取决于患者年龄和淋巴瘤类型，低级别淋巴瘤即使在老年患者中也具有良好的预后。
